TwinStrand Biosciences

TwinStrand Biosciences Duplex Sequencing patent estate is the foundational technology enabling the ability to accurately identify ultra-low frequency genomic variants that are undetectable by conventional NGS methods. The company's highly sensitive and specific patented Duplex Sequencing technology delivers clearer insights to researchers in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in public health, and other fields of science on a faster timescale when actions are most impactful. TwinStrand's scientist-leaders have authored more than thirty peer-reviewed articles using Duplex Sequencing technology and have developed a portfolio of more than 150 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks, molecular diagnostic companies and federal regulatory agencies to bring high precision genomics to the forefront of their science.

网站

https://www.twinstrandbio.com/

TwinStrand Biosciences的外部链接

所属行业

生物技术研究

规模

51-200 人

总部

Seattle，WA

类型

私人持股

领域

duplex sequencing、ultra-rare variant detection、genetic toxicity、carcinogenesis、mutagenesis、tumor evolution、error corrected sequencing、direct mutation detection、cloud-based bioinformatics、eliminating NGS noise、sequencing mutation discovery、DNA mixture deconvolution、Microhaplotypes、liquid biopsy、residual disease monitoring、minimum residual disease detection、FFPE、Next-generation sequencing、eliminating NGS background errors、targeted biomarker validation、mutation signature discovery、CRISPR validation、drug candidate selection、targeted DNA sequencing、profiling environmental exposure和early cancer detection